Skip to main content
Cardiotoxicity-induced by anti-cancer drugs is a life-threatening adverse event. The number of treatment modalities enormously increased as a result of enhancements in oncology research. This also caused an increase in the number of cardiotoxic anti-cancer agents. Published literature indicates that cardiotoxicity associated with anti-cancer drugs was observed in 1-30% of the patients. Introduction of novel therapeutics such as tyrosine-kinase inhibitors and immune check-point inhibitors were found to be associated with cardiotoxicity but have not been extensively investigated. We carry out a research project in collaboration with The Royal Marsden NHS Foundation Trust to investigate the causes of cardiotoxicity in non-small cell lung cancer populations in a real-world setting (e.g. gender, age, smoking status, etc.). Another aim of this study is to understand the true incidence of cardiotoxicity in non-small cell lung cancer patients who receive novel therapeutics. We also run several other research projects to investigate the cardio-oncology practice, worldwide.
I am a Cypriot pharmacist graduated from Eastern Mediterranean University. My thesis was on lithium-induced toxicities in North Cyprus. After my graduation, I started to do a Ph.D. at Kingston University, London in 2018. From the beginning of my undergraduate studies until now, I worked in several fields including hospital management, community pharmacy and currently working as a teaching assistant at Kingston University for the modules called Professional Pharmacy skills and Interprofessional learning. My current Ph.D. project is cardio-oncology which is a growing topic related to the management of cardiac side effects of anti-cancer drugs. Drug-related toxicities describe my main field of interest. Nowadays, I am building my career in the science of real-world evidence. I believe that clinical trials in oncology are not enough to reveal the main effects and safety of cancer drugs. Because of that, real-world studies are and should be an indispensable part of oncology trials.